Q1 2025 Hims & Hers Health Inc Earnings Call Transcript
Key Points
- Revenue grew 111% year over year to $586 million, demonstrating strong momentum.
- Subscriber base increased by 38% year over year, reaching nearly 2.4 million.
- Partnership with Novo Nordisk expands access to branded Wegovy, enhancing weight loss offerings.
- Adjusted EBITDA nearly tripled, reaching $91 million, indicating improved profitability.
- Expansion into new specialties like low testosterone and menopause support is underway, broadening service offerings.
- Gross margins declined approximately 3 points quarter over quarter due to scaling of GLP-1 revenue.
- Volatility expected in sexual health growth as the company transitions to more premium daily products.
- Marketing efficiency may experience volatility as the company leans into specialty-specific marketing.
- Transition of subscribers off commercially available semaglutide expected to result in a one-time revenue drop in Q2.
- Potential headwinds from macroeconomic factors such as tariffs could impact gross margins.
Good afternoon, ladies and gentlemen. Thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers first-quarter 2025 earnings call.
I would now like to turn the call over to Bill Newby, Head of Investor Relations. Please go ahead, sir.
Good afternoon, everyone, and welcome to the Hims & Hers Health first-quarter 2025 earnings call.
Today, after the market closed, we released this quarter's shareholder letter, a copy of which you can find on our website at investors.hims.com. On the call with me today is Andrew Dudum, our Co-Founder and Chief Executive Officer; and Yemi Okupe, our Chief Financial Officer.
Before I hand it over to Andrew, I need to remind you of legal Safe Harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on, among other things, our current market, competitors and regulatory expectations and are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
